"Although each rare disease impacts a small population, the rare disease population is estimated to be 10% of the total population, meaning 25-30 million Americans have at least one rare condition."

"Our mission is to bring novel and transformative therapies to the anterior (front) chamber of the eye, particularly for the treatment of ocular surface disease."

"AC Immune is combining diagnostics and therapeutics, and it has developed the tools to enable detection and clearance of specific pathological proteins underlying neurodegenerative diseases."

"At Vyant Bio we are reinventing how drugs are discovered for complex neurological and neurodegenerative disorders by applying a human-first approach."